【结 构 式】 |
【分子编号】68776 【品名】6-amino-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one 【CA登记号】1002726-62-6 |
【 分 子 式 】C9H11N3O2 【 分 子 量 】193.20536 【元素组成】C 55.95% H 5.74% N 21.75% O 16.56% |
合成路线1
该中间体在本合成路线中的序号:(III)Chlorination of 5-fluorouracil (I) by means of POCl3 gives 2,4-dichloro-5-fluoropyrimidine (II), which is condensed with the pyrido-[3,2-b][1,4]oxazin-3-one derivative (III) to afford the secondary amine (IV). Then, subsequent displacement of the remaining chlorine of pyrimidine (IV) with 3,4,5-trimethoxyaniline (V) yields the substituted pyrimidine-2,4-diamine (VI) . Condensation of pyridooxazinone derivative (VI) with di-tert-butyl chloromethyl phosphate (VII) prepared by chlorination of potassium di-tert-butylphosphate (VIII) with ClSO3CH2Cl by means of Bu4NHSO4 in CH2Cl2/H2O – in the presence of Cs2CO3 in acetone or DMF gives a mixture of three N-substituted regioisomers, which are then subjected to either column chromatography or crystallization on MTBE to provide the major N-substituted oxazinone (IX). Hydrolysis of the t-butyl ester groups of (IX) by means of AcOH in H2O or TFA in CH2Cl2 affords free acid (X) , which is finally treated with aqueous or IPA/H2O NaOH .
Alternatively, condensation of pyridooxazinone (VI) and chloromethyl phosphate (VII) with Cs2CO3 in DMAC at 40 °C affords the N-substituted oxazinone (IX), which is directly hydrolyzed by means of AcOH in H2O, and the phosphoric acid (X) is submitted to purification by crystallization on DMF .
【1】 Singh, R., Atuegbu, A., Ramphal, J. et al. (Rigel Pharmaceuticals, Inc.).Pyrimidinediamine kinase inhibitors. US 2010179134, WO 2010078369. |
【2】 Felfer, U., Giselbrecht, K.-H., Wolberg, M. (Rigel Pharmaceuticals, Inc.). Synthesis of N4-(2,2-dimethyl-4-[dihydrogen phosphonoxy]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine disodium salt. US 2011003986, WO 2011002999. |
【3】 Bhamidipati, S., Singh, R., Sun, T., Masuda, E. (Rigel Pharmaceuticals, Inc.). Prodrug salts of 2,4-pyrimidinediamine compounds and their uses. EP 2078026, JP 2010510322, WO 2008064274. |
【4】 Singh, R., Bhamidipati, S., Masuda, E., Stella, V.J., Sun, T. (Rigel Pharmaceuticals, Inc.). Prodrugs of 2,4-pyrimidinediamine compounds and their uses. CA 2591948, EP 1856135, EP 2161275, JP 2008527048, US 2006211657, US 7449458, WO 2006078846. |
【5】 Singh, R., Bhamidipati, S., Stella, V.J., Sun, T. (Rigel Pharmaceuticals, Inc.). Prodrugs of 2,4-pyrimidinediamine compounds and their uses. US 7563892. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 29241 | 5-fluoro-2,4(1H,3H)-pyrimidinedione;5-fluorouracil;5-Fluoro-2,4-pyrimidinedione;5-Fluoropyrimidine-2,4-dione | 51-21-8 | C4H3FN2O2 | 详情 | 详情 |
(II) | 45722 | 2,4-dichloro-5-fluoropyrimidine;2,4-Dichloro-5-fluorouracil | C4HCl2FN2 | 详情 | 详情 | |
(III) | 68776 | 6-amino-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one | 1002726-62-6 | C9H11N3O2 | 详情 | 详情 |
(IV) | 68777 | 6-((2-chloro-5-fluoropyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one | C13H11ClFN5O2 | 详情 | 详情 | |
(V) | 31545 | 3,4,5-trimethoxyaniline; 3,4,5-trimethoxyphenylamine;3,4,5-Trimethoxybenzenamine;[3,4,5-Tris(methyloxy)phenyl]amine | 24313-88-0 | C9H13NO3 | 详情 | 详情 |
(VI) | 68778 | 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one | C22H23FN6O5 | 详情 | 详情 | |
(VII) | 42239 | di(tert-butyl) chloromethyl phosphate;di-tert-butyl chloromethyl phosphate;PHOSPHORIC ACI DI-T-BUTYL EXTER CHLOROMETHYL ESTER | 229625-50-7 | C9H20ClO4P | 详情 | 详情 |
(VIII) | 68779 | potassium di-tert-butyl phosphate | C8H18KO4P | 详情 | 详情 | |
(IX) | 68780 | di-tert-butyl ((6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl) phosphate | C31H42FN6O9P | 详情 | 详情 | |
(X) | 68781 | (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl dihydrogen phosphate | C23H26FN6O9P | 详情 | 详情 |